Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

NCT00206089 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
3300
Enrollment
INDUSTRY
Sponsor class

Stopped Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.

Conditions

Interventions

Sponsor

AstraZeneca